DETECTING NEONATAL SEPSIS USING MOLECULAR TECHNIQUES

描述：（改编自研究者摘要）：约15万 到50万胎龄大于34周的婴儿被送入NICU 每年有全身感染风险的人。这些婴儿都接受 全身抗生素治疗。然而，这些婴儿中的绝大多数是 没有感染，而是有继发于其他医疗症状， 条件目前评估新生儿败血症的护理标准是 血液培养，缺乏灵敏度，在检测之前没有信息 至少24到46小时因此，长期使用抗生素治疗 对于许多新生儿来说，如果通过更快速的检测来排除这种可能性， 脓毒症可用。本申请提出研究两种潜在的 测试，用于检测细菌16S核糖体的基于PCR的扩增测定 DNA和基于ELISA的防御素测定，以确定它们作为 系统性新生儿感染的早期预测因素。

DESCRIPTION: (Adapted from the Investigator's Abstract): Approximately 150,000 to 500,000 infants greater than 34 weeks gestational age are admitted to NICUs annually who are at risk for systemic infection. These infants all receive systemic antibiotic therapy. However, the vast majority of these infants are not infected, but rather have symptoms that are secondary to other medical conditions. The current standard of care for evaluating neonatal sepsis is blood culturing, which lacks sensitivity and is not informative prior to at least 24 to 46 hours. As a result, there is prolonged use of antibiotic therapy in many newborns that could be shortened if a more rapid test to rule out sepsis was available. This application proposes to investigate two potential tests, a PCR-based amplification assay for detecting bacterial 16S ribosomal DNA and an ELISA-based assay for defensins, to determine their usefulness as early predictors of systemic neonatal infection.